Innate Pharma
IPHA
7 hedge funds and large institutions have $20.3M invested in Innate Pharma in 2020 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 2 closing their positions.
5.7% less ownership
Funds ownership: 9.34% → 3.64% (-5.7%)
30% less funds holding
Funds holding: 10 → 7 (-3)
59% less capital invested
Capital invested by funds: $49M → $20.3M (-$28.7M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$117K |
| 2 |
Morgan Stanley
New York
|
+$61.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$29.8M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Wellington Management Group
Boston,
Massachusetts
| $9.87M | +$117K | +17,428 | +1% |
|
|
RCMNY
2
Rubric Capital Management (New York)
New York
| $6.38M | – | – | – |
|
3
Adage Capital Partners
Boston,
Massachusetts
| $3.42M | – | – | – |
|
4
Millennium Management
New York
| $530K | – | – | – |
|
|
5
Morgan Stanley
New York
| $85K | +$61.2K | +9,141 | +277% |
|
6
Osaic Holdings
Scottsdale,
Arizona
| $14K | – | – | – |
|
|
SPIA
7
Steward Partners Investment Advisory
New York
| $8K | – | – | – |
|
|
EC
8
EcoR1 Capital
San Francisco,
California
| – | -$29.8M | -4,465,668 | Closed |
|
|
9
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$1K | -100 | Closed |
|
IPHA Hedge Fund Activity: Q2 2020 in Review
7 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q2 2020, worth a combined $20.3M — down 59% from $49M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of IPHA and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 2 added.
The largest buyer was Wellington Management Group, adding an estimated $117K. The largest seller was EcoR1 Capital, exiting entirely with an estimated $29.8M sold.
- 7 institutional investors held Innate Pharma (IPHA) as of Q2 2020, down from 10 in Q1 2020.
- Funds reported $20.3M of Innate Pharma stock for Q2 2020, down 59% quarter-over-quarter.
- 0 funds opened new Innate Pharma positions in Q2 2020 and 2 closed out, a net change of -2 holders.
- The largest Innate Pharma buyer in Q2 2020 was Wellington Management Group, an estimated $117K added.
- The largest Innate Pharma seller in Q2 2020 was EcoR1 Capital, an estimated $29.8M sold.
Based on aggregated 13F filings for Q2 2020.